Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot


About this study

The purpose of this study is to explain the functional change mechanism linking right atrial (RA) hypertension, right heart (RH) remodeling and onset of symptoms such as arrhythmias and impaired aerobic capacity, since symptomatic status is a risk factor for mortality in the Tetralogy of Fallot (TOF) population.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years.
  • Moderate (or greater) PR based on quantitative Doppler echocardiography.
  • Able to undergo CMRI. 

Exclusion Criteria:

  • Individiuals < 18 years.
  • Prior history of atrial or ventricular arrhythmias.
  • Current diuretics use.
  • Predicted peak velocity of < 60%.
  • Pregnant women.
  • Unable to undergo cardiac magnetic resonance imaging (CMRI).

Eligibility last updated 2/3/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Alexander Egbe, M.B.B.S., M.P.H.

Open for enrollment

Contact information:

Halley Davison

(507) 422-6246

More information


Publications are currently not available